Literature DB >> 33907935

Characteristics and outcome of varicella-zoster virus central nervous system infections in adults.

A Le Bot1, A Ballerie2, C Pronier3, F Bénézit1, F Reizine1, M Tas4, P Jégo2, M Revest1, Y Le Tulzo1, P Fillâtre5, Pierre Tattevin6.   

Abstract

We conducted an observational retrospective study of all adults hospitalized for documented varicella-zoster virus (VZV) meningitis or encephalitis during years 2000-2015 in one referral centre. Thirty-six patients (21 males, 15 females) were included, with meningitis (n = 21), or meningoencephalitis (n = 15). Median age was 51 years [interquartile range, 35-76], and 6 patients (17%) were immunocompromised. Aciclovir was started in 32 patients (89%), with a median dose of 11 mg/kg/8 h [10-15]. No patient died, but 12 (33%) had neurological sequelae at discharge. Age was the only variable associated with adverse outcome (OR 1.98 [1.17-3.35] per 10-year increment, P = 0.011).
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Encephalitis; Meningitis; Prognosis; Varicella-zoster virus

Mesh:

Substances:

Year:  2021        PMID: 33907935     DOI: 10.1007/s10096-021-04245-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  16 in total

1.  The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Allan R Tunkel; Carol A Glaser; Karen C Bloch; James J Sejvar; Christina M Marra; Karen L Roos; Barry J Hartman; Sheldon L Kaplan; W Michael Scheld; Richard J Whitley
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

Review 2.  Epidemiology of infectious encephalitis causes in 2016.

Authors:  A Boucher; J L Herrmann; P Morand; R Buzelé; Y Crabol; J P Stahl; A Mailles
Journal:  Med Mal Infect       Date:  2017-03-22       Impact factor: 2.152

3.  Guidelines on the management of infectious encephalitis in adults.

Authors:  J P Stahl; P Azouvi; F Bruneel; T De Broucker; X Duval; B Fantin; N Girard; J L Herrmann; J Honnorat; M Lecuit; A Mailles; L Martinez-Almoyna; P Morand; L Piroth; P Tattevin
Journal:  Med Mal Infect       Date:  2017-04-12       Impact factor: 2.152

4.  In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review.

Authors:  Roy F Chemaly; Joshua A Hill; Sebastian Voigt; Karl S Peggs
Journal:  Antiviral Res       Date:  2019-01-21       Impact factor: 5.970

5.  Biphasic evolution of varicella-zoster virus meningoencephalitis : Diagnostic challenges.

Authors:  F Reizine; C Pronier; C Lepart; C Grolhier; M Revest; V Thibault; P Tattevin
Journal:  Med Mal Infect       Date:  2019-11-22       Impact factor: 2.152

6.  Varicella zoster vs. herpes simplex meningoencephalitis in the PCR era. A single center study.

Authors:  Lea Pollak; Sarah Dovrat; Mazal Book; Ella Mendelson; Miriam Weinberger
Journal:  J Neurol Sci       Date:  2011-12-02       Impact factor: 3.181

7.  Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study.

Authors:  Julia Granerod; Helen E Ambrose; Nicholas Ws Davies; Jonathan P Clewley; Amanda L Walsh; Dilys Morgan; Richard Cunningham; Mark Zuckerman; Ken J Mutton; Tom Solomon; Katherine N Ward; Michael Pt Lunn; Sarosh R Irani; Angela Vincent; David Wg Brown; Natasha S Crowcroft
Journal:  Lancet Infect Dis       Date:  2010-10-15       Impact factor: 25.071

8.  Infectious encephalitis in france in 2007: a national prospective study.

Authors:  Alexandra Mailles; Jean-Paul Stahl
Journal:  Clin Infect Dis       Date:  2009-12-15       Impact factor: 9.079

9.  Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium.

Authors:  A Venkatesan; A R Tunkel; K C Bloch; A S Lauring; J Sejvar; A Bitnun; J-P Stahl; A Mailles; M Drebot; C E Rupprecht; J Yoder; J R Cope; M R Wilson; R J Whitley; J Sullivan; J Granerod; C Jones; K Eastwood; K N Ward; D N Durrheim; M V Solbrig; L Guo-Dong; C A Glaser
Journal:  Clin Infect Dis       Date:  2013-07-15       Impact factor: 9.079

10.  Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group.

Authors:  R J Whitley; J W Gnann; D Hinthorn; C Liu; R B Pollard; F Hayden; G J Mertz; M Oxman; S J Soong
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.